Next Day Disclosure Return (Equity issuer - changes in issued shares or treasury shares, share buybacks and/or on-market sales of treasury shares)

Equity issuer					Status:		Resubmission		
Genscript Biotech Corporation									
14 April 2025									
Ordinary shares	Type of shares Not		oplicable	Listed		isted on the Exchange		Yes	
01548	Description	Description					·		
hares or treasury shares		•							
Events					es in treasury shares				
		uding shares (excluding treasury shares) before		Number of treasury shares		Issue/ selling price per share (Note 4)		Total number of issued shares	
) 31 March 2025	2,15	9,938,787		0				2,159,938,787	
ransfer of treasury shares in respect of granted to a director of the issuer under a res involved	5,120,000		0.23704 %			HKD	0.481		
uant to the Pre-IPO share option scheme adopted									
4 April 2025									
Closing balance as at (Notes 5 and 6) 14 April 2025		2,165,058,787			0			2,165,058,787	
	Genscript Biotech Corporation 14 April 2025 Leted by a listed issuer where there has the Stock Exchange of Hong Kong Limites"). Ordinary shares 01548 Lete of treasury shares 131 March 2025 Lete of treasury shares in respect of granted to a director of the issuer under a res involved Lete of the issuer under a resinvolved Lete of the issuer under a resinvolved	Genscript Biotech Corporation 14 April 2025 Seted by a listed issuer where there has been a change in its interpretation in the Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Ordinary shares Ordinary shares Other Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Changes or treasury shares Changes or treasury shares Other Stock Exchange of Hong Kong Limited (the "Exchange") (les"). In the Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Changes or treasury shares Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Changes or treasury shares Other Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Changes or treasury shares Other Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Ordinary shares Other Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Ordinary shares Other Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange") (les"). Stock Exchange of Hong Kong Limited (the "Exchange")	Genscript Biotech Corporation 14 April 2025 Letted by a listed issuer where there has been a change in its issued in the Stock Exchange of Hong Kong Limited (the "Exchange") (the "Mes"). Ordinary shares Type of shares Not appeared to a Changes in interest (excluding treasury shares) Levents Number of issued shares (excluding treasury shares) 1 April 2025 2,159,938,787 5,120,000 1 April 2025	Genscript Biotech Corporation 14 April 2025 Ented by a listed issuer where there has been a change in its issued shares or treasury shares the Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rules"). Ordinary shares Type of shares Not applicable Description Changes in issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) As a % of existing number of issued shares (excluding treasury shares) before the relevant event (Note 3) 31 March 2025 2,159,938,787 ansfer of treasury shares in respect of granted to a director of the issuer under a res involved 4 April 2025	Genscript Biotech Corporation 14 April 2025 atted by a listed issuer where there has been a change in its issued shares or treasury shares which is the Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27 (les"). Ordinary shares Type of shares Not applicable O1548 Description Changes in issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) before the relevant event (Note 3) 31 March 2025 2,159,938,787 ansfer of treasury shares in respect of granted to a director of the issuer under a res involved uant to the Pre-IPO share option scheme adopted	Genscript Biotech Corporation 14 April 2025 Seted by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable in the Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules (es"). Ordinary shares Type of shares Not applicable Listed on the 01548 Description Changes in issued shares (excluding treasury shares) Changes in issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) As a % of existing number of issued shares (excluding treasury shares) before the relevant event (Note 3) 31 March 2025 2,159,938,787 0 ansfer of treasury shares in respect of granted to a director of the issuer under a res involved and to the Pre-IPO share option scheme adopted	Genscript Biotech Corporation 14 April 2025 Seted by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable pursuant to rul the Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules Governing the less"). Ordinary shares Type of shares Not applicable Listed on the Exchange O1548 Description Number of issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) before the relevant event (Note 3) Number of treasury shares) 1 Ssue/ selling treasury shares before the relevant event (Note 3) April 2025 HKD HKD	Genscript Biotech Corporation 14 April 2025 Exted by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable pursuant to rule 13.25A of the Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules Governing the Listing of Seles"). Ordinary shares Type of shares Not applicable Listed on the Exchange Yes O1548 Description Targes or treasury shares Changes in issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) Type of shares Changes in issued shares (excluding treasury shares) As a % of existing number of issued shares (excluding treasury shares) before the relevant event (Note 3) Issuel selling price per share (Note 4) Issuel selling price per share (Note 4) anster of treasury shares in respect of granted to a director of the issuer under a granted to the Pre-IPO share option scheme adopted	

Page 1 of 6 v 1.3.0

B. Shares redeemed or repurchased for cancellation but not yet cancelled as at the closing balance date (Notes 5 and 6)

Not applicable

Page 2 of 6 v 1.3.0

Confirmation

Pursuant to Main Board Rule 13.25C / GEM Rule 17.27C, we hereby confirm to the best knowledge, information and belief that, in relation to each issue of shares or sale or transfer of treasury shares as set out in Section I, it has been duly authorised by the board of directors of the listed issuer and carried out in compliance with all applicable listing rules, laws and other regulatory requirements and, insofar as applicable:

(Note 7)

- (i) all money due to the listed issuer in respect of the issue of shares, or sale or transfer of treasury shares has been received by it;
- (ii) all pre-conditions for the listing imposed by the Main Board Rules / GEM Rules under "Qualifications of listing" have been fulfilled;
- (iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled;
- (iv) all the securities of each class are in all respects identical (Note 8);
- (v) all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with all other legal requirements;
- (vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue, sale or transfer;
- (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and
- (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies.

Notes to Section I:

- 1. Please insert the closing balance date of the last Next Day Disclosure Return published pursuant to Main Board Rule 13.25A / GEM Rule 17.27A or Monthly Return pursuant to Main Board Rule 13.25B / GEM Rule 17.27B, whichever is the later.
- 2. Please set out all changes in issued shares or treasury shares requiring disclosure pursuant to Main Board Rule 13.25A / GEM Rule 17.27A together with the relevant dates of changes. Each category will need to be disclosed individually with sufficient information to enable the user to identify the relevant category in the listed issuer's Monthly Return. For example, multiple issues of shares as a result of multiple exercises of share options under the same share option scheme or of multiple conversions under the same convertible note must be aggregated and disclosed as one category. However, if the issues resulted from exercises of share options under 2 share option schemes or conversions of 2 convertible notes, these must be disclosed as 2 separate categories.
- 3. The percentage change in the number of issued shares (excluding treasury shares) of the listed issuer is to be calculated by reference to the opening balance of the number of issued shares (excluding treasury shares) being disclosed in this Next Day Disclosure Return.

Page 3 of 6 v 1.3.0

- 4. In the case of a share repurchase or redemption, the "issue/ selling price per share" shall be construed as "repurchase price per share" or "redemption price per share".
 - Where shares have been issued/ sold/ repurchased/ redeemed at more than one price per share, a volume-weighted average price per share should be given.
- 5. The closing balance date is the date of the last relevant event being disclosed.
- 6. For repurchase or redemption of shares, disclosure is required when the relevant event has occurred (subject to the provisions of Main Board Rules 10.06(4)(a), 13.25A and 13.31 / GEM Rules 13.13(1), 17.27A and 17.35), even if the repurchased or redeemed shares have not yet been cancelled.
 - If repurchased or redeemed shares are to be cancelled upon settlement of such repurchase or redemption after the closing balance date, they shall remain part of the issued shares as at the closing balance date in Part A. Details of these repurchased or redeemed shares shall be disclosed in Part B.
- 7. Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases.
- 8. "Identical" means in this context:
 - the securities are of the same nominal value with the same amount called up or paid up;
 - they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
 - they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.

Page 4 of 6 v 1.3.0

Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under Main Board Rule 10.06(4)(a) / GEM Rule 13.13(1).

Repurchase report Not applicable

Page 5 of 6 v 1.3.0

Section III must also be completed by a listed issuer where it has made a sale of treasury shares on the Exchange or any other stock exchange on which the issuer is listed which is discloseable under Main Board Rule 10.06B / GEM Rule 13.14B.

Report of on-market sale of treasury shares

Not applicable

Submitted by:	Jiange MENG
	(Name)
Title:	Director
	(Director, Secretary or other Duly Authorised Officer)

Page 6 of 6 v 1.3.0